Equillium Inc (EQ)
NASDAQ:EQ
EQ Stock Chart & Stats
$1.88
-$0.05(-6.85%)
At close: 4:00 PM EST
$1.88
-$0.05(-6.85%)
Day’s Range― - ―
52-Week Range$0.27 - $2.70
Previous CloseN/A
Volume484.47K
Average Volume (3M)883.61K
Market Cap
$118.87M
Enterprise Value$37.22M
Total Cash (Recent Filing)$30.28M
Total Debt (Recent Filing)$719.00K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
May 07, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding63,226,555
10 Day Avg. Volume862,141
30 Day Avg. Volume883,611
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)4.98
Price to Sales (P/S)1095.50
P/FCF Ratio-6.25
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-320.88
Enterprise Value/Ebitda-1.58
Forecast
1Y Price Target
$8.50Price Target Upside352.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-driven DevelopmentPhase 1 will measure tissue biomarkers that previously predicted remission, and matching those biomarker levels could allow bridging to earlier efficacy signals without a full large-scale trial.
Targeted DeliveryEquillium is developing an enteric-coated oral formulation designed to concentrate EQ504 in the colon, which could increase local drug exposure and limit systemic side effects.
Therapeutic MechanismEQ504 targets the aryl hydrocarbon receptor to reduce intestinal inflammation and promote colon tissue repair, offering a treatment approach distinct from existing ulcerative colitis therapies.
Bears Say
Preclinical Development RiskEQ504 remains in preclinical development, increasing scientific and clinical risk because human safety, optimal dosing, and therapeutic efficacy remain unproven.
Regulatory And Trial UncertaintyPreclinical status creates regulatory and trial uncertainty, which could require additional studies to confirm human benefit and complicate the path to approval.
Safety Legacy From BotanicalThe botanical that initially validated the pathway showed batch variability, poor solubility, and a systemic safety signal that halted a trial, so similar safety concerns persist until colon-targeted delivery proves to mitigate systemic risks.
Equillium News
EQ FAQ
What was Equillium Inc’s price range in the past 12 months?
Equillium Inc lowest stock price was $0.27 and its highest was $2.70 in the past 12 months.
What is Equillium Inc’s market cap?
Equillium Inc’s market cap is $118.87M.
When is Equillium Inc’s upcoming earnings report date?
Equillium Inc’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were Equillium Inc’s earnings last quarter?
Equillium Inc released its earnings results on Mar 25, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.02.
Is Equillium Inc overvalued?
According to Wall Street analysts Equillium Inc’s price is currently Undervalued.
Does Equillium Inc pay dividends?
Equillium Inc does not currently pay dividends.
What is Equillium Inc’s EPS estimate?
Equillium Inc’s EPS estimate is -0.05.
How many shares outstanding does Equillium Inc have?
Equillium Inc has 63,226,555 shares outstanding.
What happened to Equillium Inc’s price movement after its last earnings report?
Equillium Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Equillium Inc?
Currently, no hedge funds are holding shares in EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Equillium Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (352.13% Upside)
$8.50 (352.13% Upside)
Hedge Fund Trend
Decreased
By 7.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.18%
12-Months-Change
Fundamentals
Return on Equity
-148.81%
Trailing 12-Months
Asset Growth
0.14%
Trailing 12-Months
Company Description
Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
EQ Stock 12 Month Forecast
Average Price Target
$8.50
▲(352.13% Upside)
Technical Analysis
NRX Pharmaceuticals
―
Sutro Biopharma
―
MindWalk Holdings
―
Prelude Therapeutics
―
Coeptis Therapeutics Holdings
―
Ownership Overview
7.83% Insiders
3.25% Mutual Funds
33.99% Other Institutional Investors
52.17% Public Companies and
Individual Investors